Close Menu
NEW YORK – (GenomeWeb News) – Lab21 said today that it will offer five of DeCode Genetics’ tests in the UK and in Ireland, and it will have the rights to offer new tests that are not yet on the market.
 
The agreement allows the Cambridge, UK-based Lab21 to offer DeCode’s tests for type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer, and glaucoma, as well as an upcoming test for the risk of estrogen-positive breast cancer and “a pipeline” of other tests DeCode has in development. 
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.